Related Experiment Video
Updated: Jul 24, 2025

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
Enhancing the functional maturity of hiPSC-derived cardiomyocytes to assess inotropic compounds
Xiaoyu Zhang1, Praful Aggarwal2, Ulrich Broeckel2
1Agilent Technologies, San Diego, CA 92121, USA.
Insights
Long-term electrical pacing matures human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). This functional maturation enhances their ability to predict drug responses, particularly for inotropic compounds.
Area of Science:
- Cardiovascular Research
- Stem Cell Biology
- Pharmacology
Background:
- Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are valuable for in vitro drug safety testing.
- Immature hiPSC-CMs exhibit fetal-like characteristics, limiting their predictive power for certain drug effects.
- Specifically, their contractile function and calcium handling are not fully mature, hindering assessment of ionotropic compounds.
Purpose of the Study:
- To enhance the functional maturity of hiPSC-CMs for improved drug screening.
- To overcome the limitations of fetal-like phenotypes in hiPSC-CMs.
- To enable more accurate prediction of compound effects on cardiomyocyte contractility.
Main Methods:
- Utilized Agilent's xCELLigence Real-Time Cell Analyzer (RTCA) ePacer for continuous electrical pacing.
- Applied progressive electrical stimulation to hiPSC-CMs for up to 15 days.
- Monitored cardiomyocyte contraction and viability via impedance measurements.
Main Results:
- Electrical pacing reversed the inherent negative impedance amplitude frequency in hiPSC-CMs.
- Paced hiPSC-CMs showed enhanced contractility in response to positive inotropic compounds.
- Improved calcium handling and increased expression of maturation-related genes were observed.
Conclusions:
- Continuous electrical pacing can functionally mature hiPSC-CMs.
- Mature hiPSC-CMs demonstrate improved cellular responses to inotropic compounds.
- This approach enhances the utility of hiPSC-CMs for predictive safety and toxicity assessments.
Abstract:
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) present an attractive in vitro platform to model safety and toxicity assessments-notably screening pro-arrhythmic compounds. The utility of the platform is stymied by a hiPSC-CM contractile apparatus and calcium handling mechanism akin to fetal phenotypes, evidenced by a negative force-frequency relationship. As such, hiPSC-CMs are limited in their ability to assess compounds that modulate contraction mediated by ionotropic compounds (Robertson, Tran, & George, 2013). To address this limitation, we utilize Agilent's xCELLigence Real-Time Cell Analyzer ePacer (RTCA ePacer) to enhance hiPSC-CM functional maturity. A continuous, progressive increase of electrical pacing is applied to hiPSC-CMs for up to 15 days. Contraction and viability are recorded by measurement of impedance using the RTCA ePacer. Our data confirms hiPSC-CMs inherently demonstrate a negative impedance amplitude frequency that is reversed after long-term electrical pacing. The data also indicate positive inotropic compounds increase the contractility of paced cardiomyocytes and calcium handling machinery is improved. Increased expression of genes critical to cardiomyocyte maturation further underscores the maturity of paced cells. In summary, our data suggest the application of continuous electrical pacing can functionally mature hiPSC-CMs, enhancing cellular response to positive inotropic compounds and improving calcium handling. SUMMARY: Long-term electrical stimulation of hiPSC-CM leads to functional maturation enabling predictive assessment of inotropic compounds.
More Related Videos
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
07:41Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential
Published on: January 18, 2019